Navigation Links
Quanticel Pharmaceuticals Enters Into Strategic Cancer Drug Discovery Collaboration With Celgene Corporation
Date:11/4/2011

SAN FRANCISCO and SUMMIT, N.J., Nov. 4, 2011 /PRNewswire/ -- Privately held biotechnology company Quanticel Pharmaceuticals Inc. and Celgene Corporation (NASDAQ: CELG), together with Versant Ventures, today announced they have entered into an exclusive, strategic collaboration to discover and develop first-in-class cancer drugs.  

Under the terms of the agreement, Celgene will commit $45M to Quanticel during the initial three-and-a-half-year alliance term with the ability to extend the collaboration in exchange for additional funding.  Celgene will also take an equity stake in Quanticel and will retain an exclusive option to acquire the company.

During the collaboration, Quanticel will utilize its platform to conduct single-cell genomic analysis of patient tumor samples and to identify predictive biomarkers for Celgene investigational drugs.  Quanticel will also leverage its platform to perform independent drug discovery to generate its own drug candidates, and Celgene will have the ability to access this pipeline through its acquisition option.

"We all share a sense of urgency to create truly meaningful cancer medicines, and understand that new strategies that address all tumor cell populations are required for effective therapy," said Stephen Kaldor, Ph.D., Chief Executive Officer at Quanticel.  "Celgene's global research and development capabilities plus the long-term financial commitment to Quanticel enable us to rapidly build the research and development applications of our platform, and to accelerate the potential growth of our pipeline."

"Quanticel's platform approach provides a unique advantage for defining mechanisms of sensitivity and resistance, and for validating and pursuing novel targets for difficult-to-treat cancers," said Thomas Daniel, M.D., President, Global Research and Early Development at Celgene.  "We view this scientific collaboration and this business model as an innovative approach with high potential to advance the delivery of impactful cancer drugs to patients in need."

The collaboration utilizes an innovative funding structure between Quanticel, Celgene and Versant Ventures.  Versant and Celgene have worked together to capitalize Quanticel at an early juncture, providing Versant with a strategic partner and potential acquirer, and Celgene with early and exclusive access to an R&D engine capable of fostering breakthrough therapies for patients at an accelerated pace.

"Aligning our financing strategy to create a start-up that supports the needs of a pre-eminent global biopharmaceutical company such as Celgene should build even greater value and liquidity than the traditional biotech venture approach," said Bradley Bolzon, Ph.D., Managing Director, Versant Ventures.

About Quanticel Pharmaceuticals

Quanticel Pharmaceuticals is a private, independent drug discovery company committed to creating breakthrough medicines for the treatment of cancer and other life-threatening diseases.  Quanticel's proprietary platform for the single-cell genomic analysis of human cancer is based on the work of company founders and Stanford professors Stephen Quake and Michael Clarke.  Quanticel brings together pioneering academic serial entrepreneurs, proven industry talent who have produced marketed drugs and high-value liquidity events, and top-tier Bay Area investor Versant Ventures.  The Company is headquartered in San Francisco, California.  For more information, please visit the Company's website at www.quanticel.com.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

About Versant Ventures

Versant Ventures is a leading healthcare-focused venture capital firm specializing in seed, early-stage and selective later-stage investments in medical devices, biotechnology and pharmaceuticals. Founded in 1999, Versant has a world-class capability for startup incubation. The firm engineers innovative business models to create value and a path toward liquidity, and partners with both entrepreneurs and pharmaceutical companies to facilitate transactions. Several examples of the unique model in addition to Quanticel include Amira, Synosia, Flexion, Kythera, and Inception. Versant Ventures has a seasoned team of 13 managing directors with more than 170 years of venture capital investing experience and approximately 145 years of operating experience. The firm currently has more than $1.6 billion in capital and works with 95 companies in its portfolios. Versant has three offices in California in Silicon Valley, Orange County and San Francisco. For more information, please visit www.versantventures.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contact:

Quanticel Pharmaceuticals
Michele Parisi
(925) 429-1850
mparisi@biocommnetwork.com

Celgene Corporation
Investors:
Patrick E. Flanigan III
Vice President
Investor Relations
(908) 673-9969
ir@celgene.com

Media:
Brian P. Gill
Vice President
(908) 673-9530
media@celgene.com


'/>"/>
SOURCE Quanticel Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast access to ... at the point of need   ... and services, has launched a ClinicalKey mobile app that enables ... Elsevier designed the mobile app to allow users to select access to ... Android and iOS formats for mobile phone and tablet. ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists ... cell-isolation method that opens the door to genetic ... now have been impossible to isolate with 100 ... isolate specific tumor types in various stages of ... variants of these cells that are clinically relevant, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March ... Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its Third ... February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event ... the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization ...
(Date:2/11/2016)... ... February 11, 2016 , ... The book, “Computers Should ... services, what questions to ask your IT consultant before signing a contract and how ... computer network. , “With companies relying heavily on e-mail and technology, it’s more important ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
Breaking Medicine News(10 mins):